Guse Kyle 4
4 · ATOSSA GENETICS INC · Filed Jan 15, 2019
Insider Transaction Report
Form 4
Guse Kyle
CFO & General Counsel
Transactions
- Award
Stock Option (Right to Buy)
2019-01-13+800,000→ 800,000 totalExercise: $1.36Exp: 2029-01-13→ Common Shares (800,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2019-01-13−700,000→ 0 totalExercise: $2.38Exp: 2028-06-27→ Common Shares (700,000 underlying)
Footnotes (3)
- [F1]The June 27, 2018 options are being rescinded and a new option is being granted in order to: (i) impose a shareholder-approval requirement for the new option grant, and (ii) remove the cash settlement feature and associated liability from the June 27, 2018 grant.
- [F2]Twenty-five percent of the options were vested as of the grant date (June 27, 2018), 50% of the options will vest quarterly over two years from the grant date, and the remaining 25% will vest upon achievement of certain milestones.
- [F3]Subject to stockholder approval of the option grant, the option will vest and be exercisable with respect to: (i) 25% of the underlying shares as of the grant date (January 13, 2019), (ii) 50% of the underlying shares over a two-year period (vesting ratably quarterly) from June 27, 2018, and (iii) 25% of the underlying shares upon achievement of certain milestones. If the option grant is not approved by stockholders, then the option will not be exercisable.